Mineralys Therapeutics, Inc. MLYS Current ratio
Current ratio at other companies
Other financials
Where this comes from
Calculated from Mineralys Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s current ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s current ratio?
- Mineralys Therapeutics, Inc. (MLYS) reported current ratio of 44.3× in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s current ratio changed year-over-year?
- Mineralys Therapeutics, Inc.'s current ratio increased by 67.4% year-over-year, from 26.5× to 44.3×.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s current ratio?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s current ratio has grown at a 46.3% compound annual growth rate (CAGR), from 14× to 43.8×.
- What does current ratio mean?
- Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.